Get startedLog in
    Picture of Camurus AB logo

    CAMX — Camurus AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareSpeculativeLarge CapHigh Flyer
    All News

    Brief: FDA Issues Complete Response Letter For Camurus CAM2029 NDA For Acromegaly

    Picture of Camurus AB logoCamurus AB
    11/06/2026 06:36
    BRIEF-FDA Issues Complete Response Letter For Camurus CAM2029 NDA For Acromegaly
    June 11 (Reuters) - Camurus AB CAMX.ST:
    • SAID ON WEDNESDAY FDA ISSUES COMPLETE RESPONSE LETTER FOR CAMURUS CAM2029 NDA FOR ACROMEGALY
    • CRL DOES NOT RELATE TO THE CLINICAL EFFICACY OR SAFETY OF CAM2029
    • WORKING TOWARD RESUBMISSION OF NDA IN NEAR TERM, WHILE MAINTAINING LAUNCH READINESS AND WITH NO CHANGE TO 2026 FINANCIAL OUTLOOK

            
     Source text for Workspace: nWkr1vT7T
     Further company coverage: CAMX.ST 

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Camurus AB

    See all news